특수 제어 혈장 시장 규모 조사 : 유형별, 용도별, 최종사용자별, 지역별 예측(2022-2032년)

Global Specialty Control Plasma Market is valued at approximately USD 9.88 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 6.29% over the forecast period 2024-2032. Specialty control plasma is an essential laboratory product utilized in clinical diagnostics to ensure the precision and reliability of coagulation tests, such as prothrombin time (PT) and activated partial thromboplastin time (aPTT). This control plasma, derived from human or animal sources, is meticulously formulated to contain known levels of clotting factors, serving as a benchmark to validate the performance of coagulation assays. This enables laboratories to identify variations in test outcomes, thereby maintaining consistent and high-quality diagnostic results across various testing platforms.

The Global Specialty Control Plasma Market growth is propelled by significant investment in research and development activities, escalating demand for plasma-derived drugs globally, and the rising geriatric population. The increased prevalence of infectious diseases worldwide, coupled with advances in biotechnology and the expanding application of plasma-derived therapies, also drives the market. Additionally, the rapid growth of the healthcare sector and heightened consumer awareness further bolster the demand for specialty control plasma. However, high cost of associated with plasma-derived products is going to impede the overall demand for the market during the forecast period 2024-2032.

The key regions considered for the market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. In 2023, North America is poised to hold a substantial share of the specialty control plasma market, primarily due to the region's advanced development and manufacturing capabilities. The presence of major industry players in the USA and Canada offers significant growth opportunities. Meanwhile, the Asia Pacific region is expected to capture a considerable market share, driven by advancements in medical technology and the increasing prevalence of chronic disorders. The growing demand for plasma-delivered therapies and heightened awareness about plasma donation further stimulate market growth in this region.

Major market players included in this report are:

• Precision BioLogic Incorporated
• Baxter BioScience
• Grifols S.A.
• Shire Plc.
• VitroPharma
• Kedrion S.p.A.
• China Biologic Products (Shandong Taibang)
• Biotest AG
• Sanquin
• Talecris Biotherapeutics
• SK Plasma Co.
• CSL Ltd.
• Octapharma AG
• Cerus Corp.
• Hemasoft

The detailed segments and sub-segments of the market are explained below:

By Type:

• Factor VIII Concentrate
• Factor IX Concentrate
• Immunoglobulins
• Others

By Application:

• Coagulation Disorders
• Immunodeficiency Diseases
• Hypogammaglobulinemia

By End User:

• Hospitals
• Diagnostic Laboratories
• Clinics
• Others

By Region:

North America:

• U.S.
• Canada

Europe:

• UK
• Germany
• France
• Spain
• Italy
• ROE

Asia Pacific:

• China
• India
• Japan
• Australia
• South Korea
• RoAPAC

Latin America:

• Brazil
• Mexico
• RoLA

Middle East & Africa:

• Saudi Arabia
• South Africa
• RoMEA

Years considered for the study are as follows:

• Historical year - 2022
• Base year - 2023
• Forecast period - 2024 to 2032

Key Takeaways:

• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market

Table of Contents

Chapter 1. Global Specialty Control Plasma Market Executive Summary

• 1.1. Global Specialty Control Plasma Market Size & Forecast (2022-2032)
• 1.2. Regional Summary
• 1.3. Segmental Summary
  • 1.3.1. By Type
  • 1.3.2. By Application
  • 1.3.3. By End User
• 1.4. Key Trends
• 1.5. Recession Impact
• 1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Specialty Control Plasma Market Definition and Research Assumptions

• 2.1. Research Objective
• 2.2. Market Definition
• 2.3. Research Assumptions
  • 2.3.1. Inclusion & Exclusion
  • 2.3.2. Limitations
  • 2.3.3. Supply Side Analysis
    • 2.3.3.1. Availability
    • 2.3.3.2. Infrastructure
    • 2.3.3.3. Regulatory Environment
    • 2.3.3.4. Market Competition
    • 2.3.3.5. Economic Viability (Consumer's Perspective)
  • 2.3.4. Demand Side Analysis
    • 2.3.4.1. Regulatory Frameworks
    • 2.3.4.2. Technological Advancements
    • 2.3.4.3. Environmental Considerations
    • 2.3.4.4. Consumer Awareness & Acceptance
• 2.4. Estimation Methodology
• 2.5. Years Considered for the Study
• 2.6. Currency Conversion Rates

Chapter 3. Global Specialty Control Plasma Market Dynamics

• 3.1. Market Drivers
  • 3.1.1. Increasing Investment in R&D Activities
  • 3.1.2. Rising Demand for Plasma-Derived Drugs
  • 3.1.3. Growing Geriatric Population
• 3.2. Market Challenges
  • 3.2.1. High Costs Associated with Plasma-Derived Products
  • 3.2.2. Limited Availability of Donors
• 3.3. Market Opportunities
  • 3.3.1. Advances in Biotechnology
  • 3.3.2. Expanding Applications in Plasma-Derived Therapies
  • 3.3.3. Rapid Growth of Healthcare Sector

Chapter 4. Global Specialty Control Plasma Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
  • 4.1.6. Futuristic Approach to Porter's 5 Force Model
  • 4.1.7. Porter's 5 Force Impact Analysis
• 4.2. PESTEL Analysis
  • 4.2.1. Political
  • 4.2.2. Economical
  • 4.2.3. Social
  • 4.2.4. Technological
  • 4.2.5. Environmental
  • 4.2.6. Legal
• 4.3. Top investment opportunity
• 4.4. Top winning strategies
• 4.5. Disruptive Trends
• 4.6. Industry Expert Perspective
• 4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Specialty Control Plasma Market Size & Forecasts by Type 2022-2032

• 5.1. Segment Dashboard
• 5.2. Global Specialty Control Plasma Market: Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 5.2.1. Factor VIII Concentrate
  • 5.2.2. Factor IX Concentrate
  • 5.2.3. Immunoglobulins
  • 5.2.4. Others

Chapter 6. Global Specialty Control Plasma Market Size & Forecasts by Application 2022-2032

• 6.1. Segment Dashboard
• 6.2. Global Specialty Control Plasma Market: Application Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 6.2.1. Coagulation Disorders
  • 6.2.2. Immunodeficiency Diseases
  • 6.2.3. Hypogammaglobulinemia

Chapter 7. Global Specialty Control Plasma Market Size & Forecasts by End User 2022-2032

• 7.1. Segment Dashboard
• 7.2. Global Specialty Control Plasma Market: End User Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 7.2.1. Hospitals
  • 7.2.2. Diagnostic Laboratories
  • 7.2.3. Clinics
  • 7.2.4. Others

Chapter 8. Global Specialty Control Plasma Market Size & Forecasts by Region 2022-2032

• 8.1. North America Specialty Control Plasma Market
  • 8.1.1. U.S. Specialty Control Plasma Market
    • 8.1.1.1. Type breakdown size & forecasts, 2022-2032
    • 8.1.1.2. Application breakdown size & forecasts, 2022-2032
    • 8.1.1.3. End User breakdown size & forecasts, 2022-2032
  • 8.1.2. Canada Specialty Control Plasma Market
• 8.2. Europe Specialty Control Plasma Market
  • 8.2.1. UK Specialty Control Plasma Market
  • 8.2.2. Germany Specialty Control Plasma Market
  • 8.2.3. France Specialty Control Plasma Market
  • 8.2.4. Spain Specialty Control Plasma Market
  • 8.2.5. Italy Specialty Control Plasma Market
  • 8.2.6. Rest of Europe Specialty Control Plasma Market
• 8.3. Asia-Pacific Specialty Control Plasma Market
  • 8.3.1. China Specialty Control Plasma Market
  • 8.3.2. India Specialty Control Plasma Market
  • 8.3.3. Japan Specialty Control Plasma Market
  • 8.3.4. Australia Specialty Control Plasma Market
  • 8.3.5. South Korea Specialty Control Plasma Market
  • 8.3.6. Rest of Asia Pacific Specialty Control Plasma Market
• 8.4. Latin America Specialty Control Plasma Market
  • 8.4.1. Brazil Specialty Control Plasma Market
  • 8.4.2. Mexico Specialty Control Plasma Market
  • 8.4.3. Rest of Latin America Specialty Control Plasma Market
• 8.5. Middle East & Africa Specialty Control Plasma Market
  • 8.5.1. Saudi Arabia Specialty Control Plasma Market
  • 8.5.2. South Africa Specialty Control Plasma Market
  • 8.5.3. Rest of Middle East & Africa Specialty Control Plasma Market

Chapter 9. Competitive Intelligence

• 9.1. Key Company SWOT Analysis
• 9.2. Top Market Strategies
• 9.3. Company Profiles
  • 9.3.1. Precision BioLogic Incorporated
    • 9.3.1.1. Key Information
    • 9.3.1.2. Overview
    • 9.3.1.3. Financial (Subject to Data Availability)
    • 9.3.1.4. Product Summary
    • 9.3.1.5. Market Strategies
  • 9.3.2. Baxter BioScience
  • 9.3.3. Grifols S.A.
  • 9.3.4. Shire Plc.
  • 9.3.5. VitroPharma
  • 9.3.6. Kedrion S.p.A.
  • 9.3.7. China Biologic Products (Shandong Taibang)
  • 9.3.8. Biotest AG
  • 9.3.9. Sanquin
  • 9.3.10. Talecris Biotherapeutics
  • 9.3.11. SK Plasma Co.
  • 9.3.12. CSL Ltd.
  • 9.3.13. Octapharma AG
  • 9.3.14. Cerus Corp.
  • 9.3.15. Hemasoft

Chapter 10. Research Process

• 10.1. Research Process
  • 10.1.1. Data Mining
  • 10.1.2. Analysis
  • 10.1.3. Market Estimation
  • 10.1.4. Validation
  • 10.1.5. Publishing
• 10.2. Research Attributes